Published in Gastroenterology on May 01, 2007
Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med (2008) 2.78
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes (2011) 2.65
Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology (2012) 2.56
FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest (2009) 2.46
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes (2010) 2.34
Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet (2009) 2.29
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab (2008) 2.05
Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology (2008) 2.04
Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia (2008) 1.97
Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology (2010) 1.96
GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology (2011) 1.92
A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90
Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest (2011) 1.90
Modulation of taste sensitivity by GLP-1 signaling. J Neurochem (2008) 1.89
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology (2010) 1.86
Islet β cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci (2013) 1.84
Role of the gut in lipid homeostasis. Physiol Rev (2012) 1.73
Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat Med (2009) 1.68
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care (2011) 1.63
GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol (2011) 1.62
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci (2012) 1.60
Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care (2011) 1.58
Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes (2010) 1.58
Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg (2009) 1.56
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res (2012) 1.55
Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci (2011) 1.54
Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol (2017) 1.54
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care (2011) 1.53
Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes (2015) 1.50
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care (2014) 1.49
Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol (2010) 1.49
A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor. PLoS One (2014) 1.47
Glutamine triggers and potentiates glucagon-like peptide-1 secretion by raising cytosolic Ca2+ and cAMP. Endocrinology (2011) 1.47
Bitter taste receptors influence glucose homeostasis. PLoS One (2008) 1.44
Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes (2010) 1.43
Global biochemical profiling identifies β-hydroxypyruvate as a potential mediator of type 2 diabetes in mice and humans. Diabetes (2014) 1.42
iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy. Cell Metab (2016) 1.41
The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptin. BMC Gastroenterol (2011) 1.40
Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab (2011) 1.40
Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia (2012) 1.35
Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol (2009) 1.33
The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol (2012) 1.32
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol (2013) 1.31
Gut chemosensing: interactions between gut endocrine cells and visceral afferents. Auton Neurosci (2009) 1.30
Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc (2010) 1.28
Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes (2013) 1.28
Lipotoxicity disrupts incretin-regulated human β cell connectivity. J Clin Invest (2013) 1.27
Membrane-tethered ligands are effective probes for exploring class B1 G protein-coupled receptor function. Proc Natl Acad Sci U S A (2009) 1.27
The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes (2012) 1.26
Cardiovascular effects of gliptins. Nat Rev Cardiol (2013) 1.23
Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. Plant Biotechnol J (2012) 1.21
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther (2012) 1.21
Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2012) 1.20
Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg (2009) 1.20
Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic α-cells in mouse models of ß-cell regeneration. Islets (2010) 1.19
Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J Biol Chem (2011) 1.19
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol (2010) 1.17
Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. Diabetes (2008) 1.17
Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res (2012) 1.17
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol (2013) 1.16
Dietary resistant starch increases hypothalamic POMC expression in rats. Obesity (Silver Spring) (2008) 1.16
Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am (2008) 1.15
Completion of the swine genome will simplify the production of swine as a large animal biomedical model. BMC Med Genomics (2012) 1.14
An endoluminal sleeve induces substantial weight loss and normalizes glucose homeostasis in rats with diet-induced obesity. Obesity (Silver Spring) (2008) 1.13
Chronic activation of a designer G(q)-coupled receptor improves β cell function. J Clin Invest (2013) 1.13
Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care (2013) 1.13
The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab (2014) 1.13
Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci (2009) 1.12
The metabolic actions of glucagon revisited. Nat Rev Endocrinol (2010) 1.12
Taste cells of the gut and gastrointestinal chemosensation. Mol Interv (2008) 1.11
Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice. Endocrinology (2015) 1.11
Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care (2011) 1.10
Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J Biol Chem (2009) 1.10
Gene-environment interactions controlling energy and glucose homeostasis and the developmental origins of obesity. Physiol Rev (2015) 1.10
Sensing via intestinal sweet taste pathways. Front Neurosci (2011) 1.09
Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav (2012) 1.09
Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab (2008) 1.09
Vertical sleeve gastrectomy improves glucose and lipid metabolism and delays diabetes onset in UCD-T2DM rats. Endocrinology (2012) 1.09
Therapy in the early stage: incretins. Diabetes Care (2011) 1.08
Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am J Physiol Gastrointest Liver Physiol (2009) 1.08
Genetic analysis for a shared biological basis between migraine and coronary artery disease. Neurol Genet (2015) 1.08
Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol (2010) 1.07
A model of GLP-1 action on insulin secretion in nondiabetic subjects. Am J Physiol Endocrinol Metab (2010) 1.07
Ileal interposition improves glucose tolerance and insulin sensitivity in the obese Zucker rat. Am J Physiol Gastrointest Liver Physiol (2010) 1.07
Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res (2012) 1.06
Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol (2010) 1.06
Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol (2009) 1.06
Nutrient detection by incretin hormone secreting cells. Physiol Behav (2011) 1.06
CRFR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner. Proc Natl Acad Sci U S A (2009) 1.04
Obesity, gut hormones, and bariatric surgery. World J Surg (2009) 1.04
Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. J Neurosci (2012) 1.04
Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol (2011) 1.04
Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications. Front Endocrinol (Lausanne) (2012) 1.04
GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes (2012) 1.03
Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology (2009) 1.03
Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol (2012) 1.03
Diabetes remission without weight loss after duodenal bypass surgery. Surg Obes Relat Dis (2011) 1.02
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N Engl J Med (2015) 6.48
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation (2008) 4.22
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med (2003) 3.57
Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol (2009) 3.43
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med (2011) 3.31
GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab (2006) 3.28
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem (2002) 3.08
Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab (2013) 2.60
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest (2002) 2.54
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology (2012) 2.48
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology (2010) 2.33
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med (2013) 2.31
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe (2013) 2.14
Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab (2007) 2.12
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest (2004) 2.11
Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol (2008) 2.03
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest (2005) 2.01
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest (2006) 1.96
Modulation of taste sensitivity by GLP-1 signaling. J Neurochem (2008) 1.89
Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes (2006) 1.83
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol (2009) 1.79
Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci (2003) 1.74
Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology (2009) 1.74
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med (2013) 1.72
Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology (2005) 1.71
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes (2010) 1.71
Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes (2013) 1.64
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes (2009) 1.62
The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab (2008) 1.58
Clinical decisions. Management of type 2 diabetes. N Engl J Med (2008) 1.58
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept (2005) 1.57
Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes (2003) 1.55
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology (2004) 1.53
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology (2007) 1.45
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology (2010) 1.42
beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes (2005) 1.41
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation (2012) 1.39
Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes (2007) 1.39
Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes (2012) 1.29
Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology (2003) 1.28
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest (2011) 1.27
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes (2003) 1.26
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology (2008) 1.26
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology (2011) 1.25
Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes (2007) 1.24
GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol (2007) 1.24
Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes (2008) 1.24
Glucagon-like Peptide-2. Annu Rev Nutr (2006) 1.22
Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes (2008) 1.22
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens (2009) 1.21
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest (2011) 1.20
Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology (2007) 1.20
Cytokines tumor necrosis factor-α and interferon-γ induce pancreatic β-cell apoptosis through STAT1-mediated Bim protein activation. J Biol Chem (2011) 1.20
ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology (2009) 1.17
Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes (2012) 1.17
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol (2013) 1.16
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Physiol Regul Integr Comp Physiol (2014) 1.16
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab (2008) 1.15
Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology (2009) 1.15
Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci (2009) 1.12
Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes (2011) 1.10
Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes (2009) 1.10
The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology (2008) 1.10
The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology (2004) 1.09
Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med (2006) 1.07
Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology (2005) 1.06
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev (2014) 1.06
Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes (2006) 1.05
ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology (2010) 1.04
Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes (2004) 1.04
A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice. Diabetes (2007) 1.02
Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB J (2009) 1.01
GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology (2010) 1.01
Insulin action in the double incretin receptor knockout mouse. Diabetes (2007) 1.00
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol (2012) 1.00
Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology (2010) 1.00
Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am J Physiol Regul Integr Comp Physiol (2006) 0.98
Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem (2002) 0.98
Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet (2008) 0.96
Glucagon receptor signaling is essential for control of murine hepatocyte survival. Gastroenterology (2008) 0.93
Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology (2010) 0.93
Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity. J Lipid Res (2012) 0.92
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res (2008) 0.92
Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiology (Bethesda) (2005) 0.92
Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes (2013) 0.91
Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology (2012) 0.90
Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. Treat Endocrinol (2002) 0.90
Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology (2011) 0.89
Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract Res Clin Endocrinol Metab (2004) 0.88
Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care (2006) 0.88
Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol Cell Biol (2005) 0.87
Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One (2011) 0.86
Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes (2008) 0.86